Ayesha Shaukat, Afsheen Q Khan, Rumaisa Riaz, Ummara Batool, Abdullah Malikzai
{"title":"Retifanlimab: a breakthrough for the management of Merkel cell carcinoma","authors":"Ayesha Shaukat, Afsheen Q Khan, Rumaisa Riaz, Ummara Batool, Abdullah Malikzai","doi":"10.1097/ij9.0000000000000116","DOIUrl":null,"url":null,"abstract":"Merkel cell carcinoma (MCC) is a rare, highly metastatic cutaneous neuroendocrine cancer originating from specialized Merkel cells, which are responsible for touch sensation in the skin. It is characterized by a firm, rapidly expanding nodule on sun-exposed skin areas, especially the head and neck. It has a high mortality rate, with reported overall survival rates ranging from 14% for distant disease to 51% for local disease. In March 2023, retifanlimab (Zynyz) received accelerated U.S. Food and Drug Administration (FDA) approval for treating adults with metastatic or recurrent locally advanced MCC. This drug offers a first-line response against MCC by improving the body’s immune response against cancer cells. This article aims to provide updated guidelines on the properties, dosing, and mechanism of action while discussing its use for the management of adults.","PeriodicalId":42930,"journal":{"name":"International Journal of Surgery-Oncology","volume":null,"pages":null},"PeriodicalIF":0.3000,"publicationDate":"2023-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Surgery-Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/ij9.0000000000000116","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Merkel cell carcinoma (MCC) is a rare, highly metastatic cutaneous neuroendocrine cancer originating from specialized Merkel cells, which are responsible for touch sensation in the skin. It is characterized by a firm, rapidly expanding nodule on sun-exposed skin areas, especially the head and neck. It has a high mortality rate, with reported overall survival rates ranging from 14% for distant disease to 51% for local disease. In March 2023, retifanlimab (Zynyz) received accelerated U.S. Food and Drug Administration (FDA) approval for treating adults with metastatic or recurrent locally advanced MCC. This drug offers a first-line response against MCC by improving the body’s immune response against cancer cells. This article aims to provide updated guidelines on the properties, dosing, and mechanism of action while discussing its use for the management of adults.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
